DTIL | tickerfilter.com

Fundamental analysis

28%

Profitability 18%

Dept financing 19%

Liquidity 75%

Performance 30%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

0.22%

1 Month

-9.41%

3 Months

-18.95%

6 Months

-48.78%

1 Year

-66.62%

2 Year

503.76%

Key data

Stock price

$4.62

P/E Ratio

4.08

DAY RANGE

$4.51 - $4.72

EPS

$1.55

52 WEEK RANGE

$3.61 - $14.66

52 WEEK CHANGE

-$67.26

MARKET CAP

29.227 M

YIELD

N/A

SHARES OUTSTANDING

7.234 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-12-2025

BETA

0.66

PUBLIC FLOAT

AVERAGE 10 VOLUME

$123,143

AVERAGE 30 VOLUME

$143,825

Company detail

CEO: Michael Amoroso
Region: US
Website: precisionbiosciences.com
Employees: 200
IPO year: 2019

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Precision BioSciences offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which a specific type of immune cell, called a T cell, is genetically engineered to recognize and kill cancer cells. PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL.

DTIL - PRECISION BIOSCIENCES INC